| 000 | 01878 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250518010844.0 | ||
| 264 | 0 | _c20190204 | |
| 008 | 201902s 0 0 eng d | ||
| 022 | _a2052-1707 | ||
| 024 | 7 |
_a10.1002/prp2.442 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChintalgattu, Vishnu | |
| 245 | 0 | 0 |
_aUtility of Glycosylated TIMP3 molecules: Inhibition of MMPs and TACE to improve cardiac function in rat myocardial infarct model. _h[electronic resource] |
| 260 |
_bPharmacology research & perspectives _c12 2018 |
||
| 300 |
_ae00442 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aADAM17 Protein _xantagonists & inhibitors |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aCell Line |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aExtracellular Matrix _xdrug effects |
| 650 | 0 | 4 | _aFibroblasts |
| 650 | 0 | 4 | _aGlycosylation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aInjections, Intralesional |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMatrix Metalloproteinases _xmetabolism |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aMyocardial Infarction _xdrug therapy |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xchemistry |
| 650 | 0 | 4 |
_aTissue Inhibitor of Metalloproteinase-3 _xchemistry |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVentricular Function, Left _xdrug effects |
| 700 | 1 | _aGreenberg, Joanne | |
| 700 | 1 | _aSingh, Shivani | |
| 700 | 1 | _aChiueh, Venice | |
| 700 | 1 | _aGilbert, Amy | |
| 700 | 1 | _aO'Neill, Jason W | |
| 700 | 1 | _aSmith, Stephen | |
| 700 | 1 | _aJackson, Simon | |
| 700 | 1 | _aKhakoo, Aarif Y | |
| 700 | 1 | _aLee, TaeWeon | |
| 773 | 0 |
_tPharmacology research & perspectives _gvol. 6 _gno. 6 _gp. e00442 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/prp2.442 _zAvailable from publisher's website |
| 999 |
_c29074605 _d29074605 |
||